Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS3351 in EGFR-Mutated Advanced NSCLC
2022-502595-23-00Phase 2Completed
- Sponsor
- Taiho Oncology
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of TAS3351 in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Taiho Oncology. Started Jul 2023; status: completed.
02
Drugs
TAS3351
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-502595-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502595-23-00.